Clinical performance is complex and often involves multiple systemic stresses. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching a team of domestic and foreign experts with accurate diagnosis and treatment plans. Treatment and management of the treatment for the anti-synthetic syndrome of Blys require individual development, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, etc. In recent years, with the development of therapeutic-focused, immune-regulatory therapies and precision medicine, many previously difficult-to-treat autoimmune and rheumatic immune disorders have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of Blys with anti-synthetase syndrome. The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of autoimmunity and rheumatic immunity, to provide the following services to patients: 1.
Remote pre-diagnosis: Pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2. Interviews in China: Arrangement with authoritative experts for face-to-face diagnosis, development of personalized treatment plans; 3. Full-service: One-stop services: medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: Establishment of a chronic disease management file, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.